Topibac1%

Established / FDA-approved use

Topibac ointment is indicated for the topical treatment of impetigo (up to 100 cm² total area in adults, or up to 2% of total body surface area in pediatric patients aged 9 months and older) caused by susceptible isolates of Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes.

Not indicated for

• Deeper, extensive, or bullous skin infections requiring systemic antibiotic therapy.
• Infections caused by methicillin-resistant Staphylococcus aureus (MRSA); Topibac has not been shown to be effective against these strains.
• Use on mucous membranes, in or near the eyes, or intraoral/intranasal/intravaginal use.

There are currently no well-established off-label uses of Topibac supported by major guidelines; its labeled indication is limited to superficial impetigo of limited extent.

Each gram of Retapamulin ointment contains Retapamulin 1% w/w as the active ingredient, in a white, soft-paraffin based ointment vehicle. Locally available brands are typically supplied as a 1% ointment in tubes (commonly 5 g or 10 g).

Topibac is a semisynthetic antibiotic belonging to the pleuromutilin class, derived from the natural compound pleuromutilin. It is formulated as a topical ointment for dermatological use and was the first pleuromutilin antibiotic approved for use in humans. Topibac is active against common Gram-positive skin pathogens responsible for impetigo and works by a mechanism distinct from other topical antibiotics such as mupirocin or fusidic acid, which is useful in areas with rising resistance to older topical agents.

Topical antibacterial agent — Pleuromutilin class (used for Topibac and no other approved pleuromutilin currently marketed for topical skin infections)

Mechanism of action

Retapamulin inhibits bacterial protein synthesis by binding to a unique site on the bacterial 50S ribosomal subunit (interacting with the L3 protein near the peptidyl transferase center), which prevents the formation of active 50S ribosomal subunits and blocks normal P-site tRNA interactions. This mechanism is distinct from macrolides, lincosamides, and other topical antibacterials, which reduces the likelihood of cross-resistance.

Pharmacokinetics

Systemic absorption of Retapamulin after topical application is minimal in patients with intact or mildly compromised skin barrier, and any absorbed drug is highly bound to plasma proteins. Because systemic exposure is negligible under labeled use conditions, plasma concentration-based dosing adjustments are generally not required.

• Wash and dry the affected area gently before application unless otherwise directed.
• Apply a thin layer of Topibac ointment using a clean fingertip or applicator, covering the lesion and a small margin of surrounding skin.
• The treated area may be covered with a sterile bandage or gauze dressing if desired.
• Wash hands after application unless the hands are the area being treated.
• Do not apply Topibac in or near the eyes, inside the mouth or nose, or on other mucous membranes.
• Avoid occlusive wrapping that is not breathable, and avoid combining with other topical products on the same area unless advised by a physician.

Because systemic absorption of Topibac after topical use is minimal, clinically significant systemic drug-drug interactions have not been established. No well-verified, clinically significant interactions with other systemic medications have been reported in labeling.

As a general precaution, avoid applying other topical medicines, cosmetics, or products to the same skin area at the same time as Topibac unless directed by a physician, as this could alter local absorption or increase irritation.

Topibac is generally well tolerated when used as directed. The most commonly reported adverse reaction is:

• Application site irritation (reported in approximately 2% or fewer of patients) — usually mild.

Other reactions reported in fewer than 2% of patients include application site pruritus (itching), headache, and diarrhea. If severe local irritation, rash, or signs of allergic reaction (swelling, difficulty breathing, hives) occur, discontinue Topibac and seek medical attention.

Pregnancy

Systemic absorption of Topibac after topical application is expected to be minimal, and adequate, well-controlled human studies in pregnancy are lacking. As with most topical medicines used during pregnancy, Topibac should be used only if clearly needed and if the potential benefit justifies the potential (though likely low) risk to the fetus; consult a physician before use during pregnancy.

Lactation

Because systemic exposure following topical use of Topibac is expected to be negligible, breastfeeding is not expected to result in meaningful exposure of the infant to the drug. As a precaution, avoid applying Topibac directly to the breast/nipple area before nursing, and consult a physician if extensive use is needed while breastfeeding.

• Not for mucosal or systemic use: Topibac is for external skin use only. Do not use in or near the eyes, or on the lips, inside the mouth, nose, or vagina.
• Local irritation/sensitization: If signs of severe local irritation or an allergic/sensitization reaction develop, discontinue Topibac and seek medical evaluation (see Contraindications for hypersensitivity).
• Limited spectrum and extent: Topibac is intended only for limited, superficial impetigo lesions as specified; it is not appropriate for deep, extensive, or systemic infections, which require alternative or systemic therapy.
• Reassess if no improvement: If there is no improvement in the treated lesions within 3 to 5 days of starting Topibac, or if the condition worsens, the patient should seek medical evaluation to reconsider the diagnosis or the need for systemic antibiotic therapy.
• Antimicrobial resistance: Use of Topibac in the absence of a proven or strongly suspected susceptible bacterial infection is unlikely to provide benefit and increases the risk of development of drug-resistant bacteria.
• Antibiotic stewardship: Take Topibac exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.

Topical overdose with Topibac has not been reported. Accidental ingestion of the ointment or extensive application beyond the recommended area is unlikely to cause serious systemic toxicity given the drug's minimal absorption, but is not recommended. If accidental ingestion, application to a very large area, or a significant allergic reaction occurs, seek immediate medical attention or contact a poison control center / emergency services rather than attempting home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep the tube tightly closed and out of the reach of children.

Renal impairment

No dose adjustment of Topibac is expected to be necessary in renal impairment, given the negligible systemic absorption after topical application; formal renal dosing studies have not been conducted.

Hepatic impairment

No dose adjustment of Topibac is expected to be necessary in hepatic impairment for the same reason; formal hepatic dosing studies have not been conducted.

Elderly

Limited data are available in elderly patients, but no specific dose adjustment of Topibac is anticipated based on its topical, minimally absorbed nature.

Pediatric

Topibac is approved for use in children 9 months of age and older; safety and efficacy in infants younger than 9 months have not been established, and higher relative systemic exposure has been observed in younger infants, so use below 9 months is not recommended.

Pleuromutilin antibiotics; Topical antibacterials/dermatological anti-infectives

Category B (FDA legacy pregnancy category)

Topibac is indicated for impetigo in pediatric patients 9 months of age and older, using the same twice-daily, 5-day regimen but limited to a maximum of 2% of total body surface area. Safety and efficacy in infants younger than 9 months have not been established, and this age group should not use Topibac outside of specific physician guidance, since younger infants have shown relatively higher systemic drug exposure after topical application.